MAZEMaze Therapeutics, Inc.
Price
+18%1YEnd-of-day closes, not the intraday tick.
The five questions
2 of 5 availableOnly two of the five can be answered for MAZE today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with kidney and metabolic diseases. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants associated with health and disease and then determine how these drive risk for and protection against disease in specific patient groups through a process we refer to as variant functionalization.
In the company’s own words · 10-K filed Mar 25, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Maze Therapeutics, Inc. (MAZE) reported revenue of $0 in Q2 2026 (quarter ended Jun 30, 2026). That came with net loss of $45M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 17, 2026On August 13, 2026, the Board of Directors (the “Board”) of Maze Therapeutics, Inc. (the “Company”) appointed Paula A. Johnson, M.D., M.P.H. as a Class III director and Sophie Kornowski, Pharm.D. as a Class I director, in each case effective August 13, 2026 (the “Appointment Date”)Director or officer change · Form 8-K
- Aug 11, 2026Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights.Earnings release · press release
- May 22, 2026On May 18, 2026, Amy Bachrodt gave notice that she will resign as Senior Vice President, Finance of Maze Therapeutics, Inc. (the “Company”), effective June 1, 2026.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Biotechnology
The closest names by size in the same industry